Cision PR Newswire

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

–ย  ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandiยฎ (enzalutamide), the ability to overcome Xtandi resistance,... Read more.
Press Release
Back to top button